Negative symptoms in schizophrenia: correlation with clinical and genetic factors.
Aline HajjSouheil AllitKaram ChamounHala SacreSahar ObeidChadia HaddadSonia DollfusLydia Rabbaa KhabbazPublished in: Pharmacogenomics (2021)
Aim: Explore the possible association between clinical factors and genetic variants of the dopamine pathways and negative symptoms. Materials & methods: Negative symptoms were assessed in 206 patients with schizophrenia using the Arabic version of the self-evaluation of negative symptoms scale and the Positive and Negative Syndrome Scale. Genotyping for COMT, DRD2, MTHFR and OPRM1 genes was performed. Results: Multivariable analysis showed that higher self-evaluation of negative symptoms scale scores were significantly associated with higher age, higher chlorpromazine-equivalent daily dose for typical antipsychotics and in married patients. Higher negative Positive and Negative Syndrome Scale scores were significantly associated with women and having the CT genotype for MTHFR c.677C>T (β = 4.25; p = 0.008) compared with CC patients. Conclusion: Understanding both clinical/genetic factors could help improve the treatment of patients.
Keyphrases
- end stage renal disease
- genome wide
- newly diagnosed
- ejection fraction
- prognostic factors
- chronic kidney disease
- computed tomography
- magnetic resonance
- pregnant women
- metabolic syndrome
- bipolar disorder
- dna methylation
- high throughput
- skeletal muscle
- depressive symptoms
- psychometric properties
- positron emission tomography
- patient reported